To the Editor: In the article regarding cognitive function in patients receiving the proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab, Giugliano et al. (Aug. 17 issue)1 report that evolocumab does not affect neurocognition, even in patients who attained very low levels of low-density lipoprotein (LDL) cholesterol. In the EBBINGHAUS trial (Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects), Giugliano et al. prospectively assessed cognitive function across a wide range of domains, including memory and attention. However, no test was performed to evaluate depressive symptoms specifically. Depression negatively affects performance on cognitive tests and may . . .

中文翻译：

---

Evolocumab随机试验中的认知功能

致编者：Giugliano等人，在有关接受前蛋白转化酶枯草杆菌蛋白酶-kexin 9型（PCSK9）抑制剂的患者的认知功能的文章中。（8月17日发行）1报告称，即使在低密度脂蛋白（LDL）胆固醇水平非常低的患者中，evolocumab也不影响神经认知。在EBBINGHAUS试验（评估PCSK9结合抗体对高心血管风险受试者的认知健康的影响）中，Giugliano等人。对包括记忆和注意力在内的广泛领域的前瞻性评估认知功能进行评估。但是，没有进行任何测试来专门评估抑郁症状。抑郁对认知测试的表现有负面影响，并可能。。。